Mr. Todd Shapiro reports

RED LIGHT HOLLAND'S WHOLLY OWNED SUBSIDIARY, FILAMENT HEALTH, SIGNS AGREEMENT TO SUPPLY PEX010 BOTANICAL PSILOCYBIN DRUG CANDIDATE FOR MILITARY VETERANS PTSD STUDY AT ARQ NATIONAL PSYCHOTRAUMA CENTRE

Following Red Light Holland Corp.'s acquisition of Filament Health Corp., the company has expanded its pharmaceutical-grade manufacturing, regulatory and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010.

The company is pleased to announce that Filament has signed an agreement with ARQ National Psychotrauma Centre (ARQ), a leading mental health care institute in the Netherlands focused on the treatment of psychotrauma related disorders, to supply PEX010 in support of an academic clinical study, titled "Psilocybin-Assisted Psychotherapy for Posttraumatic Stress Disorder in Military Veterans: A Pilot Feasibility Study."

The study is a pilot feasibility study examining psilocybin-assisted psychotherapy in military veterans living with posttraumatic stress disorder. PEX010 will be supplied as the investigational drug product for the study. Research of this kind, conducted within a highly specialized psychotrauma treatment setting, supports a patient population for whom existing treatments often fall short and reflects a long-standing clinical commitment to those affected by trauma sustained in service.

PEX010 has now been supplied to more than 80 academic and clinical studies worldwide, making it the natural psilocybin drug candidate of choice for leading research institutions and one of the most widely studied botanical psilocybin drug candidates in regulated clinical research.

"Veteran suicide is something that breaks my heart. These are people who give so much to protect their countries and protect our freedoms, and helping veterans has always been a personal priority for me," said Todd Shapiro, chief executive officer and director of Red Light Holland. "Being able to support this study with a reliable supply of PEX010 is something we are very proud of, and I am hopeful that it can lead to wider opportunities to increase access to PEX010 for veterans and the clinicians working to give them new and effective options."

About Red Light Holland Corp.

Red Light is an Ontario-based organization advancing a focused strategy within the legal psychedelic sector, centred on consensual data collection and R&D (research and development) initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experiences. In parallel, the company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands' legal market and mushroom home grow kits offered through B2B (business-to-business) and DTC (direct-to-consumer) channels, in compliance with applicable laws.

About Filament Health Corp.

Filament Health is a clinical-stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally derived psychedelic medicines can improve the lives of many and its mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development and delivery of natural psychedelic medicines for clinical development. Filament is paving the way with the first-ever natural psychedelic drug candidates.

About ARQ National Psychotrauma Centre

ARQ National Psychotrauma Centre, based in Diemen, the Netherlands, is the country's leading institute in the field of psychotrauma, bringing prevention, diagnosis, treatment, scientific research and education together under one roof. Its specialized treatment centre, ARQ Centrum '45, provides highly specialized diagnostics and treatment for people with complex and treatment-resistant psychotrauma symptoms, including military veterans, and has a long history of developing innovative therapies for this population.

We seek Safe Harbor.